Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioma 2Brain Neoplasms 2Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Gliosarcoma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 29Bevacizumab 15Radiotherapy 13antineoplaston AS 2-1 8antineoplaston A10 8Everolimus 7Radiation 6Erlotinib Hydrochloride 6Radiotherapy, Intensity-Modulated 5Lomustine 4veliparib 3palbociclib 3Vorinostat 3Sunitinib 3Radiotherapy, Conformal 3Magnetic Resonance Spectroscopy 3Carmustine 3Carboplatin 3temsirolimus 2selinexor 2poly ICLC 2etoposide phosphate 2cabozantinib 2Sirolimus 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Imatinib Mesylate 2Etoposide 2Donepezil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Astrocytoma × octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡